Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02716103 · ClinicalTrials.gov registry record
Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis
A clinical trial, sponsored by Boston Medical Center.
- Completed
- Registry status
- 45
- Enrollment target
NCT02716103 is a clinical trial that has completed, run by Boston Medical Center. The registered enrollment target is 45 participants.
The verdict
NCT02716103 has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
Study Summary
In this study, the investigators seek to evaluate bone marrow and blood samples and treatment responses to see if Minimal Residual Disease (MRD) can be used as a predictive method of response to treatment in amyloidosis.
Interventions
- OTHER blood collection
- OTHER bone marrow collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2016-11-21 |
| Est. Completion | 2020-09-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02716103
The ClinicalTrials.gov registry entry for NCT02716103 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which blood collection is the first listed.
NCT02716103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02716103 about?
NCT02716103 is a clinical study titled "Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis". In this study, the investigators seek to evaluate bone marrow and blood samples and treatment responses to see if Minimal Residual Disease (MRD) can be used as a predictive method of response to treatment in amyloidosis.
What is the current status of trial NCT02716103?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2016-11-21. Estimated completion is 2020-09-04.
What interventions are being tested in trial NCT02716103?
The interventions under investigation include: blood collection (OTHER), bone marrow collection (OTHER).
Who is sponsoring clinical trial NCT02716103?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.